A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

被引：0
|
作者：
Roche Kapoor
Matthew P. Deek
Riley McIntyre
Natasha Raman
Megan Kummerlowe
Iyah Chen
Matt Gaver
Hao Wang
Sam Denmeade
Tamara Lotan
Channing Paller
Mark Markowski
Michael Carducci
Mario Eisenberger
Tomasz M. Beer
Daniel Y. Song
Theodore L. DeWeese
Jason W. Hearn
Stephen Greco
Curtiland DeVille
Neil B. Desai
Elisabeth I. Heath
Stanley Liauw
Daniel E. Spratt
Arthur Y. Hung
Emmanuel S. Antonarakis
Phuoc T. Tran
机构：
[1] Sidney Kimmel Comprehensive Cancer Center,Department of Radiation Oncology and Molecular Radiation Sciences
[2] Johns Hopkins Hospital,Department of Medical Oncology
[3] Sidney Kimmel Comprehensive Cancer Center,The James Buchanan Brady Urological Institute and Department of Urology
[4] Johns Hopkins Hospital,Department of Pathology
[5] Johns Hopkins University School of Medicine,OHSU Knight Cancer Institute
[6] Johns Hopkins University School of Medicine,Department of Radiation Oncology
[7] Oregon Health & Science University,Department of Radiation Oncology
[8] University of Michigan,Karmanos Cancer Institute, Department of Oncology
[9] University of Texas Southwestern Medical Center,Department of Radiation Oncology and Cellular Oncology
[10] Wayne State University School of Medicine,Department of Radiation Medicine
[11] University of Chicago,undefined
[12] OHSU Knight Cancer Institute,undefined
[13] Oregon Health & Science University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Recurrent prostate cancer; Salvage radiation therapy (SRT); High-risk prostate cancer; Enzalutamide; Prostatectomy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response
    Hussain, M.
    Sternberg, C. N.
    Efstathiou, E.
    Fizazi, K.
    Shen, Q.
    Lin, X.
    Sugg, J.
    Steinberg, J.
    Noerby, B.
    De Giorgi, U.
    Shore, N.
    Saad, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S544 - S545
  • [32] A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early stage breast cancer
    Borgquist, Signe
    Jensen, Maj-Britt
    Ewertz, Marianne
    Jensen, Anders Bonde
    Ahern, Thomas P.
    Cronin-Fenton, Deirdre
    Christiansen, Peer
    Ejlertsen, Bent
    CANCER RESEARCH, 2020, 80 (04)
  • [33] CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Piulats, J. M.
    Smith, M.
    Matsubara, N.
    Zhang, T.
    Agarwal, N.
    Mckay, R. R.
    Johnston, E.
    Sherwood, S.
    Schaverien, C.
    Fasnacht, N.
    Lithio, A.
    Nacerddine, K.
    Todenhoefer, T.
    EUROPEAN UROLOGY, 2023, 83 : S757 - S757
  • [34] CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Matsubara, Nobuaki
    Mckay, Rana R.
    Piulats, Josep M.
    Todenhofer, Tilman
    Zhang, Tian
    Fasnacht, Nicolas
    Sherwood, Sarah
    Johnston, Erica L.
    Schaverien, Clare
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS
    Riess, H.
    Manges, R.
    Karasek, P.
    Humblet, Y.
    Barono, C.
    Santoro, A.
    Wojcik-Tomaszewska, J.
    Assadourian, S.
    Hatteville, L.
    Vincent, G.
    Philip, P.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [36] Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
    Saad, Fred
    Efstathiou, Eleni
    Attard, Gerhardt
    Flaig, Thomas W.
    Franke, Fabio
    Goodman, Oscar B., Jr.
    Oudard, Stephane
    Steuber, Thomas
    Suzuki, Hiroyoshi
    Wu, Daphne
    Yeruva, Kesav
    De Porre, Peter
    Brookman-May, Sabine
    Li, Susan
    Li, Jinhui
    Thomas, Shibu
    Bevans, Katherine B.
    Mundle, Suneel D.
    McCarthy, Sharon A.
    Rathkopf, Dana E.
    LANCET ONCOLOGY, 2021, 22 (11): : 1541 - 1559
  • [37] Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
    Jones, R.
    Casbard, A.
    Carucci, M.
    Smith, J.
    Ingarfield, K.
    Gee, J. M. W.
    Hudson, Z.
    Alchami, F.
    Hayward, L.
    Hickish, T.
    Hwang, D.
    McAdam, K.
    Spensley, S.
    Waters, S.
    Wheatley, D.
    Beresford, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1151 - S1151
  • [38] Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 17 - 18
  • [39] A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer
    Corr, Bradley
    Haggerty, Ashley
    Gysler, Stefan
    Taylor, Sarah
    Behbakht, Kian
    Alldredge, Jill
    Lefkowits, Carolyn
    Brubaker, Lindsay
    Bouts, Catherine
    Babayan, Lisa Marie
    Hopp, Samantha
    Hu, Junxiao
    Guntupalli, Saketh
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S63 - S63
  • [40] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE).
    Chi, Kim N.
    Rathkopf, Dana E.
    Attard, Gerhardt
    Smith, Matthew Raymond
    Efstathiou, Eleni
    Olmos, David
    Small, Eric Jay
    Lee, Ji Youl
    Ricci, Deborah S.
    Simon, Jason S.
    Zhao, Xin
    Kothari, Nishi
    Cheng, Shinta
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345